Anticancer activity of tyrosine kinase TrkA receptors antagonist GK-1 in experiment on mice with mammary gland adenocarcinoma Ca755
The aim of this study was to evaluate the effect of original tyrosine kinase TrkA antagonist GK-1 on tumor growth, median lifespan and hematological parameters in experiment on female mice C57Bl/6 with mammary gland adenocarcinoma Ca755. 14-day intraperitoneal administration of GK-1 at a dose of 10...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC “Publisher OKI”
2024-11-01
|
| Series: | Фармакокинетика и Фармакодинамика |
| Subjects: | |
| Online Access: | https://www.pharmacokinetica.ru/jour/article/view/427 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The aim of this study was to evaluate the effect of original tyrosine kinase TrkA antagonist GK-1 on tumor growth, median lifespan and hematological parameters in experiment on female mice C57Bl/6 with mammary gland adenocarcinoma Ca755. 14-day intraperitoneal administration of GK-1 at a dose of 10 mg/kg resulted in a significant tumor growth inhibition (TGI) on the 9th, 15th, and 21st day of adenocarcinoma Ca755 development. TGI on the 21st day was 60 %. Administration of GK-1 at doses of 1 mg/kg and 10 mg/kg significantly increased median lifespan of experimental animals by 53 % and 47% respectively. Median lifespan was calculated using the Kaplan-Meier survival analysis. Median lifespan of active control group was 18 days, in groups that received GK-1 at doses of 1 mg/kg and 10 mg/kg median lifespan was 30 days. Hematological parameters of experimental animals were not altered by administration of GK-1. Double injection of the doxorubicin on the 2nd and the 4th day of tumor development at dose of 4 mg/kg resulted in TGI by 73% on the 21st day of experiment, increase in lifespan was 58% and median lifespan was 31 days. Our data show that further investigation of the antitumor activity of GK-1 may bring promising results. |
|---|---|
| ISSN: | 2587-7836 2686-8830 |